Influenza causes respiratory diseases and often leads to large epidemics. Every year about 290,000 to 650,000 people die due to influenza worldwide. Anti-viral drugs available to treat influenza have many limitations making vaccination the most effective tool to prevent seasonal and pandemic influenza outbreaks. Influenza vaccination is highly recommended for vulnerable people such as individuals above 60 years of age, comorbid individuals having chronic metabolic diseases, pregnant women, and children.
Currently, available influenza vaccines are either inactivated or live attenuated influenza viruses. The prime challenge with existing influenza vaccine is the antigenic diversity and variability that results in accumulation of mutation in antigenic regions and compromises the efficacy of existing influenza vaccines putting threat to the management of influenza. The World Health Organization reviews the global influenza data every year and determines the strain of influenza most likely to circulate next season. This approach makes the influenza vaccine highly predictive and reduces efficacy. The influenza vaccine efficacy seen so far is in between 10 to 60%.
Various approaches are under development to improve the efficacy of influenza vaccines such as the generation of the replication-deficient viruses, use of adjuvants, application of nanotechnologies, virus-like protein particles, recombinant DNA technology, peptide and nucleic acid-based vaccines. Efforts are being made to generate broad-spectrum influenza vaccines, generally known as universal influenza vaccines, that can provide long-lasting protection against a wide variety of influenza strains across all age groups, and eliminate the need of updating influenza vaccine every season.
Another challenge comes from currently used manufacturing technique based on chicken eggs that have the risk of introduction of mutations in the antigen, potential allergy against egg proteins, slow production process. New technologies such as cell-based and plant-based manufacturing approach can overcome most of the limitations associated with egg-based production.
This Frost Radar™ analyses companies with vaccine candidates and clinical developments for next generation of influenza vaccine.
Strategic Imperative
Strategic Imperative (continued)
Growth Environment
Growth Environment (continued)
Growth Environment (continued)
Frost Radar™: Transformative Influenza Vaccines
Frost Radar™
Frost Radar™
BiondVax Pharmaceuticals Ltd.
Blue Water Vaccines
DistributedBio
Emergex Vaccines
FluGen Inc.
Imutex
Medicago
Novavax
Osivax
Seqirus
Vaxart
Vivaldi Biosciences
Strategic Insights
Significance of Being on the Frost Radar™
Frost Radar™ Empowers the CEO’s Growth Team
Frost Radar™ Empowers Investors
Frost Radar™ Empowers Customers
Frost Radar™ Empowers the Board of Directors
Frost Radar™: Benchmarking Future Growth Potential
Frost Radar™: Benchmarking Future Growth Potential
Legal Disclaimer
Frost Radar™: Benchmarking Future Growth Potential 2 Major Indices, 10 Analytical Ingredients, 1 Platform
Growth Index
Growth Index (GI) is a measure of a company’s growth performance and track record, along with its ability to develop and execute a fully aligned growth strategy and vision; a robust growth pipeline system; and effective market, competitor, and end-user focused sales and marketing strategies.
- Market Share (previous 3 years)
This is a comparison of a company’s market share relative to its competitors in a given market space for the previous 3 years. - Revenue Growth (previous 3 years)
This is a look at a company’s revenue growth rate for the previous 3 years in the market/industry/category that forms the context for the given Frost Radar™. - Growth Pipeline
This is an evaluation of the strength and leverage of a company’s growth pipeline system to continuously capture, analyze, and prioritize its universe of growth opportunities. - Vision and Strategy
This is an assessment of how well a company’s growth strategy is aligned with its vision. Are the investments that a company is making in new products and markets consistent with the stated vision? - Sales and Marketing
This is a measure of the effectiveness of a company’s sales and marketing efforts in helping it drive demand and achieve its growth objectives.
Innovation Index
Innovation Index (II) is a measure of a company’s ability to develop products/ services/ solutions (with a clear understanding of disruptive Mega Trends) that are globally applicable, are able to evolve and expand to serve multiple markets and are aligned to customers’ changing needs.
- INNOVATION SCALABILITY
This determines whether an organization’s innovations are globally scalable and applicable in both developing and mature markets, and also in adjacent and non-adjacent industry verticals. - RESEARCH AND DEVELOPMENT
This is a measure of the efficacy of a company’s R&D strategy, as determined by the size of its R&D investment and how it feeds the innovation pipeline. - PRODUCT PORTFOLIO
This is a measure of a company’s product portfolio, focusing on the relative contribution of new products to its annual revenue. - MEGATRENDS LEVERAGE
This is an assessment of a company’s proactive leverage of evolving, long-term opportunities and new business models, as the foundation of its innovation pipeline. - CUSTOMER ALIGNMENT
This evaluates the applicability of a company’s products/services/solutions to current and potential customers, as well as how its innovation strategy is influenced by evolving customer needs.
Significance of Being on the Frost Radar™
Companies plotted on the Frost RadarTM are the leaders in the industry for growth, innovation, or both. They are instrumental in advancing the industry into the future.
- GROWTH POTENTIAL
Your organization has significant future growth potential, which makes it a Company to Action. - BEST PRACTICES
Your organization is well positioned to shape Growth Pipeline™ best practices in your industry. - COMPETITIVE INTENSITY
Your organization is one of the key drivers of competitive intensity in the growth environment. - CUSTOMER VALUE
Your organization has demonstrated the ability to significantly enhance its customer value proposition. - PARTNER POTENTIAL
Your organization is top of mind for customers, investors, value chain partners, and future talent as a significant value provider.
Speak directly with our analytics experts for tailored recommendations.
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Frost Radar |
|---|---|
| No Index | No |
| Podcast | No |
| Author | Harshal Patil |
| Industries | Healthcare |
| WIP Number | D9C3-01-00-00-00 |
| Is Prebook | No |
Frost Radar™:Transformative Influenza Vaccines, 2020
A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines
29-Oct-2020
Global
Frost Radar
